person

Robert W Buchanan, MD

Robert Buchanan, MD
as of 2026-07-01
Monitor thisAsk about this
at a glance
Roles: Principal Investigator
KOL signal score 5
0 publications · 0 high-value
Synthesized from structured facts only — each point cited above.

Profile

Affiliation
University of Maryland, College Park
Roles
Principal Investigator
KOL signal
5
Publications
0 (0 high-value)
Trial investigator
yes

Trials led

8
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
NCT00547118Phase 2Terminated
Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00056498Phase 4Completed
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
NCT02008773Phase 2Completed
Anti-Inflammatory Treatment of Schizophrenia
NCT01514682—Completed
Salsalate for Insulin Resistance in Schizophrenia
NCT01182727—Completed
Oxytocin and CBSST for People With Schizophrenia
NCT01752712—Completed
Treating Refractory Schizophrenia With rTMS
NCT02242578—Terminated
Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum Disorders
NCT04418011—Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
PRINCIPAL_INVESTIGATOR
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
trial
Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
trial
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
trial
Anti-Inflammatory Treatment of Schizophrenia
trial
Salsalate for Insulin Resistance in Schizophrenia
trial